Farcast Biosciences is a biotechnology company that specializes in developing computational tools to enhance the understanding of complex biological systems. Their platform integrates diverse data types to model diseases and identify potential therapeutic targets, with a focus on oncology and immunology.

Farcast Biosciences

Farcast is human tumor microdynamics platform that predicts clinical response based on data from live human tumors. Our mission is to tell the truth about every patient tumor, every time and help improve outcomes for cancer patients.

Techstars

Accel

RA Capital Management

Sands Capital Ventures

Peak XV Partners

Alumni Ventures

Northpond Ventures

Satish Sankaran, Nandini Pal Basak, Kowshik Jaganathan, Biswajit Das, PhD, Jaromy Kuhl, David Bellar PhD FACSM FNSCA RFSA
#precisionmedicine #precisiononcology

Thank you for the overwhelming response to our posters presented at  the AACR meeting in Orlando earlier this month. Here is a link to the abstracts of our posters:
Poster 6632: Comparing response of Pembrolizumab and Nivolumab in the same patient by treating their tumors in an ex-vivo setting:
https://lnkd.in/gk-VHNBb
Poster 4568: Rescuing TKI failed RCC patients with Nivolumab
https://lnkd.in/gKATdWns
To download our AACR 2023 posters, visit us at 
https://lnkd.in/g4Kb8uw

Using Farcast's TruTumor technology, tumors from 6 HNSCC patients were simultaneously treated with Nivolumab and Pembrolizumab. The Tumor Microdynamic response was measured and compared using multi-omic assays.
To find out more about TruTumor and its versatile applications:
visit www.farcastbio.com or contact us at biopharma@farcastbio.com  
#immunooncology #precisiononcology #translationalresearch #trutumor #

The key to improving response rates and delivering durable benefits to patients is in understanding the dynamics and complexity of human tumor microenvironments. Johanna's excellent review is not only insightful, but also thought provoking!
Farcast hTMD (human Tumor Micro Dynamics) platform is based on understanding the mechanism and complexity of living human tumor fragments. 
We have curated a list of biomarkers associated with response and resistance to immune-checkpoint treatment. To download a free summary https://lnkd.in/gUvXVDUj

Tumors constantly shape their micro-environment by dynamic  signaling and communication with immune cells and constantly alter the immune and extracellular milieu. This allows tumor cells to create a tumor-supportive environment and induce neo-angiogenesis,  as well as activate a variety of mechanisms to hijack the micro-environment. 
Fighting cancer requires a deep understanding of tumor microdynamics and an intelligent decoding of myriad signals in every tumor, so that we can deliver durable benefits by directing appropriate therapies personalized for every tumor.
#tumormicroenvironment, #translationalresearch #immunooncology #tumormicrodynamics #cancerresearch #personalizedmedicine #precisiononcology

Farcast does not have any exposure to SVB and remains unaffected by the recent developments in the bank

It is hard to anticipate the activation of antitumor immune response during immunotherapy. The success of any immunotherapy is multifactorial and results from complex interplay between tumor, immune and stromal microenvironments.

For instance, PD-1/PD-L1 blockade is associated with multiple functional attributes of immunity. While numerous biomarkers exist for multiple tumor types, an accurate identification of responder phenotype is still evasive.

To find out more
https://lnkd.in/gUvXVDUj

Understanding tumor microdynamics is key to predicting response to immunotherapy.  When faced with failures like HPD,  use of combination therapies could come to rescue if one could ascertain the spatial and temporal intra-tumoral variability.

COM:FARCASTBIO

Farcast Biosciences

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

monthly webtraffic

monthly webtraffic growth

stage

raised capital

Description

invested in

investor of

Metrics